Does cannabidiol have a role in the treatment of schizophrenia?

Gururajan, Anand; Malone, Daniel Thomas

doi:10.1016/j.schres.2016.06.022

Cited by 39 publications

(27 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the present study and previous work points towards potential neurophysiological mechanisms underlying the antipsychotic and anxiolytic effects of CBD, the precise molecular mechanism(s) remain incompletely understood. Preclinical and in vitro work suggests that the effects of CBD may be mediated by various mechanisms, including negative allosteric modulation of the CB1 receptor 84 , inhibition of anandamide hydrolysis 85 , actions on 5-HT1A receptors 86 , vanilloid type 1 receptors 85 , GPR55 receptors 87 , 88 , modulation of the glutamate system 89 and various other mechanisms 90 , 91 . Further preclinical evidence points to neuroprotective, antioxidant and anti-inflammatory properties of CBD 10 .…”

Section: Discussionmentioning

confidence: 99%

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

et al. 2020

View full text Add to dashboard Cite

Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised to a single oral dose of CBD (600 mg) or placebo. Healthy controls (n = 19) were studied under identical conditions but did not receive any drug. Participants were scanned with functional magnetic resonance imaging (fMRI) during a fearful face-processing paradigm. Activation related to the CHR state and to the effects of CBD was examined using a region-of-interest approach. During fear processing, CHR participants receiving placebo (n = 15) showed greater activation than controls (n = 19) in the parahippocampal gyrus but less activation in the striatum. Within these regions, activation in the CHR group that received CBD (n = 15) was intermediate between that of the CHR placebo and control groups. These findings suggest that in CHR patients, CBD modulates brain function in regions implicated in psychosis risk and emotion processing. These findings are similar to those previously evident using a memory paradigm, suggesting that the effects of CBD on medial temporal and striatal function may be task independent.

show abstract

Section: Discussionmentioning

confidence: 99%

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Despite controversies, CBD is known to ameliorate hyperlocomotion and PPI deficits in acute models of schizophrenia (Zuardi et al, 2012). From the mechanistic perspective, however, CBD's actions on psychosis-relevant brain regions is still unclear (Gururajan and Malone, 2016), thus making electrophysiological experiments on this matter highly desirable. For example, interrogating whether CBD attenuates the effects of PCP, ketamine, or amphetamine on gamma oscillations and single-unit activity will begin to clarify CBD's antipsychotic properties.…”

Section: Implications From Rodent Electrophysiology and Research Dirementioning

confidence: 99%

Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research

et al. 2017

View full text Add to dashboard Cite

Much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. Such methods continue to map fundamental mechanisms of sensorimotor gating, hyperlocomotion, social interaction, and underlying monoaminergic, glutamatergic, and GABAergic disturbances. These strategies will require, however, a greater use of neurophysiological tools to better inform clinical research. In this sense, electrophysiology and viral vector-based circuit dissection, like optogenetics, can further elucidate how exogenous cannabinoids worsen (e.g., tetrahydrocannabinol, THC) or ameliorate (e.g., cannabidiol, CBD) schizophrenia symptoms, like hallucinations, delusions, and cognitive deficits. Also, recent studies point to a complex endocannabinoid-endovanilloid interplay, including the influence of anandamide (endogenous CB1 and TRPV1 agonist) on cognitive variables, such as aversive memory extinction. In fact, growing interest has been devoted to TRPV1 receptors as promising therapeutic targets. Here, these issues are reviewed with an emphasis on the neurophysiological evidence. First, we contextualize imaging and electrographic findings in humans. Then, we present a comprehensive review on rodent electrophysiology. Finally, we discuss how basic research will benefit from further combining psychopharmacological and neurophysiological tools.

show abstract

“…Treatment options are limited and a better understanding of the brain mechanisms involved might lead to novel treatments. Although THC in particular has been implicated in the development of psychosis or schizophrenia [6,7], several recent reviews have suggested that CBD may be beneficial in a number of psychiatric disorders including psychosis [8][9][10]. However, there is substantial variability in experimental power, methodology, dosing and experimental protocols used, and the mechanism of any antipsychotic-like effect of CBD remains unclear.…”

Section: Introductionmentioning

confidence: 99%

“…Previous locomotor hyperactivity studies in rats and mice have shown variable effects of CBD, with some showing an effect of lower but not higher doses, others only higher doses, while some have looked at acute doses and others following repeated administration [8,12] (see also Discussion). In the present study we used our standard protocols and investigated the effect of acute administration of a moderate dose of CBD to antagonize the locomotor hyperactivity induced by treatment with methamphetamine or MK-801.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Cannabidiol on Psychosis-like Behaviour Induced by Methamphetamine and MK-801 in Mice: A Negative Report

2019

J Psychiatry Brain Sci

View full text Add to dashboard Cite

Background: Cannabis is a widely used illicit substance but may also have medicinal properties. Cannabidiol (CBD), one of the main compounds of interest in the cannabis plant, has been suggested to have beneficial effects in various psychiatric disorders including anxiety and psychosis. Drug-induced locomotor hyperactivity is a commonly used animal model of psychosis-like behaviour and to show antipsychotic drug action. Several genetic and developmental animal models of psychosis show differences in locomotor hyperactivity. The aim of the present study was to investigate the effect of pretreatment with CBD on psychosis-like behaviour in mice. Methods:The animals underwent 5 sessions of locomotor activity testing each, with 3-4 days between tests to allow washout of acute drug challenge. Groups of mice (n = 8 male mice and n = 8 female mice combined) were pretreated with CBD (10 mg/kg) or its vehicle, followed 1 h later with either saline, the dopamine releaser, methamphetamine (1 or 3 mg/kg), or the NMDA receptor antagonist, MK-801 (0.1 or 0.25 mg/kg).Results: There was no significant effect of CBD on its own on locomotor activity. Pretreatment with CBD had no effect on the hyperlocomotion induced by either dose of methamphetamine. There was also no effect of CBD on MK-801 induced hyperlocomotion following the 0.25 mg/kg dose, while 0.1 mg/kg MK-801 did not induce hyperactivity. Conclusions:These results do not support an antipsychotic action of CBD.

show abstract

Does cannabidiol have a role in the treatment of schizophrenia?

Cited by 39 publications

References 135 publications

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research

The Effect of Cannabidiol on Psychosis-like Behaviour Induced by Methamphetamine and MK-801 in Mice: A Negative Report

Contact Info

Product

Resources

About